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Background.  Amplified copy number in the plasmepsin II/III genes within Plasmodium falciparum has been associated with 
decreased sensitivity to piperaquine. To examine this association and test whether additional loci might also contribute, we per-
formed a genome-wide association study of ex vivo P. falciparum susceptibility to piperaquine.
Methods.  Plasmodium falciparum DNA from 183 samples collected primarily from Cambodia was genotyped at 33 716 genome-
wide single nucleotide polymorphisms (SNPs). Linear mixed models and random forests were used to estimate associations between 
parasite genotypes and piperaquine susceptibility. Candidate polymorphisms were evaluated for their association with dihydroarte-
misinin-piperaquine treatment outcomes in an independent dataset.
Results.  Single nucleotide polymorphisms on multiple chromosomes were associated with piperaquine 90% inhibitory concen-
trations (IC90) in a genome-wide analysis. Fine-mapping of genomic regions implicated in genome-wide analyses identified multiple 
SNPs in linkage disequilibrium with each other that were significantly associated with piperaquine IC90, including a novel mutation 
within the gene encoding the P. falciparum chloroquine resistance transporter, PfCRT. This mutation (F145I) was associated with 
dihydroartemisinin-piperaquine treatment failure after adjusting for the presence of amplified plasmepsin II/III, which was also 
associated with decreased piperaquine sensitivity.
Conclusions.  Our data suggest that, in addition to plasmepsin II/III copy number, other loci, including pfcrt, may also be 
involved in piperaquine resistance.
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Artemisinin-based combination therapies (ACTs) are used 
worldwide and have contributed to reductions in the malaria 
burden in many areas. In response to inadequate efficacy of 
ACTs such as artesunate-mefloquine and artemether-lumefan-
trine [1, 2], dihydroartemisinin-piperaquine became the drug 
of choice to treat multidrug-resistant Plasmodium falciparum in 
regions of Southeast Asia plagued by artemisinin resistance. In 
addition, dihydroartemisinin-piperaquine is being used in field 
evaluations of targeted mass treatment to eliminate malaria 
within the Greater Mekong subregion in hopes of arresting 
the spread of resistance [3]. However, dihydroartemisinin-pip-
eraquine efficacy rates as low as 46% have been reported in 
regions of western Cambodia where artemisinin resistance is 
well established [4–6], and decreased in vitro piperaquine sus-
ceptibility has been seen in parasites collected from these areas 
[7, 8]. These findings suggest the emergence of piperaquine 
resistance in addition to existing artemisinin resistance, which 
bodes poorly for the ability to treat P. falciparum in this part of 
the world.
Molecular assays to detect markers of antimalarial drug resis-
tance are valuable surveillance tools. Mutations within PfKelch13 
have been identified and genetically confirmed as markers of 
resistance to the artemisinins [9–11]. Two recent studies have 
indicated that copy number variation in the plasmepsin II and III 
genes, located on chromosome 14 of P. falciparum, may serve as a 
molecular marker for decreased piperaquine sensitivity [12, 13]; 
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however, other loci may be involved. Using samples collected 
from Cambodia, we performed a genome-wide association 
study of ex vivo P.  falciparum susceptibility to piperaquine to 
identify candidate resistance loci. Here we report that in, addi-
tion to plasmepsin II/III copy number, other loci are associated 
with decreased piperaquine sensitivity, including a novel muta-
tion within the pfcrt gene.
METHODS
Study Samples
Samples used in the genome-wide association study were col-
lected from individuals with clinical malaria participating in 1 
of the 3 following studies (Supplementary Table 1): (1) a clini-
cal trial of artesunate conducted in Battambang province from 
2006–2007 (n = 30) [14]; (2) a malaria survey conducted from 
2009–2014 in 8 Cambodian provinces: Battambang, Pailin, 
Koh Kong, Kampot, Kampong Speu, Oddar Meanchey, Preah 
Sihanouk, and Preah Vihear (n = 145) [7]; and (3) a single-arm 
clinical evaluation of artesunate-mefloquine conducted in 
Kanchanaburi province, Thailand (n = 8). One hundred eighty-
three samples had both genotypes and phenotypes available.
Samples used in the validation dataset (n = 53) were collected 
as part of a therapeutic efficacy study conducted in Oddar 
Meanchey province that assessed the efficacy of a 3-day course 
of dihydroartemisinin-piperaquine [5]. In this study, using 
polymerase chain reaction (PCR) genotyping of P.  falciparum 
msp1, msp2, and glurp, the PCR-adjusted 42-day recrudescence 
rate was found to be 54% by modified intention-to-treat anal-
ysis [5].
Samples were collected under informed consent as approved 
by the Walter Reed Army Institute of Research and local 
in-country institutional review boards and were approved for 
use by the University of Maryland School of Medicine.
Parasite Genotypes
DNA extracted from leukocyte-depleted venous blood was gen-
otyped using a P. falciparum–specific NimbleGen 4.2M probe 
DNA microarray that types a total of 33 716 single nucleotide 
polymorphisms (SNPs) [15]. One hundred seventeen isolates 
also underwent whole-genome sequencing using Illumina HiSeq 
2000, using 101 base pair–paired end reads, without prior ampli-
fication. Illumina sequencing was also performed separately at 
the University of North Carolina to generate whole-genome 
sequence data for the 53 additional samples used as a valida-
tion dataset [16]. Statistics describing the breadth of genome 
coverage and read depth for both datasets can be found in 
Supplementary Table 2. Single nucleotide polymorphism calling 
for both datasets was performed at University of Maryland fol-
lowing Genome Analysis Toolkit’s best practices [17–19] using 
Unified Genotyper v3.1.1. Single nucleotide polymorphisms 
were filtered on phred-based quality score, read depth, strand 
bias, and mapping quality to generate a high-confidence SNP 
call set. The SNP array data have been submitted to the National 
Institutes of Health Gene Expression Omnibus for public access 
(www.ncbi.nlm.gov/geo/; accession number: GSE100704). 
Whole genome sequences were submitted to GenBank (acces-
sion numbers: SAMN06175892–SAMN06176015).
Phenotype
Ex vivo piperaquine 90% inhibitory concentrations (IC90s) 
were assessed using a histidine-rich protein-2 enzyme-linked 
immunosorbent assay (HRP-2 ELISA) as previously described 
[20, 21]. All assays were performed in the same laboratory at 
the Armed Forces Research Institute of Medical Science [21]. 
Piperaquine concentrations in the assay ranged 0.9–674 nM, 
including a no drug control. In 2013, we began to observe iso-
lates with the ability to grow in the maximum concentration of 
drug used in the standard range. As a result, starting in 2014, 
an increased range of piperaquine concentrations (3.4–53 905 
nM) was used in addition to the standard dilutions. To estimate 
piperaquine IC90 of parasites that grew in the maximum con-
centration of drug from the standard range (0.9–674 nM), the 
curves were replotted by fitting “zero-growth” HRP-2 optical 
density values at the extrapolated piperaquine concentration of 
53 905 nM. Dose–response curves for isolates with a range of 
susceptibilities have been described previously [20, 22]. Ninety 
percent inhibitory concentration was used as the phenotype 
because it was better correlated with treatment outcome in our 
validation dataset and in other studies [20] compared with IC50. 
A recent article also reported that IC90 values were more reliable 
than IC50 values when quantifying differences in piperaquine 
susceptibility [23]. The piperaquine survival assay [8] was not 
performed on isolates included in this study.
ADMIXTURE Analysis and Single Nucleotide Polymorphism Imputation
ADMIXTURE 1.23 [24] was used to group parasites into sub-
populations for the purpose of imputation and to adjust for 
confounding in the association analysis. The number of subpop-
ulations, K, was varied from 1 to 15, with 10 replicate runs per 
K. Cross-validation errors were used to determine the appropri-
ate K. Parasites clustered into 6 subpopulations. Ancestry values 
were used from the replicate with the greatest log-likelihood,
and isolates were assigned to a subpopulation based on their
greatest ancestry value (Supplementary Figure 1).
Beagle version 3.3.2 [25] was used to impute missing SNP 
calls for all isolates included in the genome-wide association 
analysis. Missing SNP calls were not imputed for whole-ge-
nome sequences in the fine-mapping analysis of genomic 
regions identified in the genome-wide association analysis. 
A 2-step approach was applied to impute the missing genotypes. 
Parasites with 100% ancestry values in each subpopulation were 
imputed within that subpopulation, and these imputed “pures” 
were used as a reference set to impute admixed parasites. A gen-
otype probability of 90% was used to call an imputed SNP.
Quality Control
The proportion of missing SNP calls was plotted by SNP and 
by sample. Invariant nucleotide positions across 183 samples, 
SNPs with >40% missing calls, and samples with >40% miss-
ing calls were excluded before analysis. These criteria resulted 
in the removal of 28 253 SNPs (23 271 invariant SNPs and 
4982 with a high proportion of missing calls) and 30 samples. 
An additional 2751 SNPs with minor allele frequency <5% 
were removed before analysis. After quality control, the final 
genome-wide association analysis included 2712 SNPs and 153 
samples.
Correspondence Between Genetic Subpopulations
A hierarchical clustering approach using a proportional dis-
tance matrix, performed on previously published P. falciparum 
sequences from Cambodia [26] (Dwivedi et al, submitted), was 
used to determine the correspondence between genetic subpop-
ulations in this study and those from the Dwivedi study. A total 
of 2474 SNPs from 320 samples (153 from this study and 167 
from the Dwivedi study) were used in the analysis. Dwivedi and 
colleagues have shown that stable clusters can be obtained with 
as few as 1000 SNPs. The correspondence between the subpop-
ulations is shown in Supplementary Figures 2 and 3.
Regression
Genome-wide mixed model association (GEMMA) [27] 
was used to estimate the association between each SNP and 
log10-transformed piperaquine IC90 (treated as a continuous 
variable), adjusting for genetic subpopulation, the presence of 
mutations in the kelch13 gene, and the first 3 principal com-
ponents of a principal components analysis. Principal com-
ponents were estimated from a matrix of pair-wise sample 
identity-by-state metrics [28]. An identity-by-state allele-shar-
ing matrix was included as a random effect to account for the 
correlation between genetically similar individuals that results 
from population structure. The GEMMA method was used 
to estimate coefficients and P values. A Bonferroni threshold 
(0.05/number of SNPs analyzed) was used to evaluate genome-
wide significance. Quantile-quantile plots for P values were 
used to assess the robustness of modeling approaches in min-
imizing false-positive results due to population structure or 
other confounding.
Random Forests
Random forest analyses [29] were done using the randomForest 
package [30] of the R statistical computing environment [31]. 
Because there is not an explicit way to control for confound-
ing due to population structure in random forests, analysis was 
performed within the genetic subpopulation containing most 
parasites with the highest IC90 values (subpopulation 2, n = 22). 
The number of variables tested at each split ranged 323–1097, 
and the number of trees in the forest was 100 000. The impor-
tance of each SNP in predicting log-transformed piperaquine 
IC90 (treated as a continuous variable) was assessed based on 
the percentage increase in mean-squared error.
Linkage Disequilibrium
The program Haploview [32] was used to determine linkage 
disequilibrium (LD) around SNPs associated with piperaquine 
susceptibility in genome-wide analyses. Linkage disequilib-
rium windows were defined to include all SNPs upstream and 
downstream of the associated SNP or mutation of interest up 
to but not including the next SNP with minor allele frequency 
(MAF) > 0.05 and R2 < 0.3. For associated SNPs, LD windows 
(Supplementary Table 3) were defined within parasites with the 
highest IC90 values (ie, log10 IC90 > 3.0) in genetic subpopulation 
2 to avoid false LD estimates due to population structure.
Gene Copy Number Analysis
Copy number variation was assessed across the 117 samples for 
which whole-genome sequences were generated. Raw paired-
end sequences from each sample were aligned against the P. fal-
ciparum 3D7 (PlasmoDB version 24) reference sequence using 
bowtie2 (version 2.2.4) [33]. For each sample, we calculated the 
number of reads that overlap known coding sequence intervals 
based on the P. falciparum 3D7 reference annotation general 
feature format file. The overlapping reads for each sample were 
normalized by mean coverage of the sample. Gene coverage 
in P. falciparum telomeric and internal hypervariable repeat 
regions [34] was excluded. Linear regression was used to model 
normalized coverage of P. falciparum core genes as a function 
of log-transformed piperaquine IC90. To estimate the number 
of copies of the plasmepsin II and III genes within samples with 
whole genome sequence data, copy number variations across 
chromosome 14 were determined by applying a previously 
described procedure [34].
Association With Treatment Outcome
Cox proportional hazards was used to model the time to P. fal-
ciparum recurrence in individuals with a given mutation (eg, 
PfCRT F145I or amplified plasmepsin II/III copy number) com-
pared with those without that mutation in the independently 
sequenced validation dataset. Hazard ratios (HRs) and 95% 
confidence intervals (CIs) were estimated using SAS v.9.3.
RESULTS
A total of 183 samples had both SNP array data and ex vivo phe-
notypes available (Supplementary Table 1). After quality con-
trol, a total of 2712 SNPs and 153 samples were included in the 
final genome-wide association analysis. Of these 153 samples, 
117 successfully underwent whole-genome sequencing for use 
in fine-mapping and copy number variation analyses.
Phenotype Distribution
The distribution of log-transformed piperaquine IC90s is shown in 
Figure 1 (Supplementary Table 4). Parasites with the highest IC90s 
clustered into the same genetic subpopulation (subpopulation 2, 
n = 22). Parasites from subpopulation 2 corresponded with the arte-
misinin-resistant KH2.2 subpopulation from a study conducted by 
Dwivedi and colleagues (Dwivedi et al, submitted) (Supplementary 
Figure 2). No parasites from this study corresponded with the arte-
misinin-sensitive ancestral Southeast Asian subpopulation KH1.1 
from the Dwivedi study (Supplementary Figure 3).
Genome-Wide Associations
Ten SNPs on chromosomes 6, 10, 11, 12, and 14 achieved 
genome-wide significance in linear mixed models of the 
association between each SNP on the array and piperaquine 
IC90 (Figure 2). The random forests analysis identified an SNP 
on chromosome 11 as the best predictor of piperaquine IC90 
(MAL11:1816380), with SNPs on chromosomes 7, 8, 9, 10, and 
14 also being among the top predictors of log-transformed IC90 
(Figure 3). All SNPs from the array that were associated with 
piperaquine susceptibility are shown in Supplementary Table 5.
Fine-Mapping Using Whole-Genome Sequences
Regions of LD are defined for each SNP in Supplementary 
Table  5 (Supplementary Table  3). From these regions of the 
genome, all SNPs identified in parasites that underwent 
whole-genome sequencing were included in linear mixed mod-
els of the association between log-transformed piperaquine 
IC90 and each locus. Nineteen SNPs, many of which were in 
perfect LD with each other, achieved genome-wide significance 
and had a positive coefficient (ie, the nonreference allele was 
associated with the phenotype) (Table 1). These loci included 
the SNP encoding a mutation at position 145 within the pfcrt 
gene (F145I), SNPs within a large region of chromosome 10, 
and SNPs on chromosomes 9 and 14. Based on gene ontol-
ogy classification in PlasmoDB, only 1 gene in Table  1, pfcrt, 
has a predicted function related to drug response, transport, or 
hemoglobin metabolism.
Copy Number Analysis
Linear regression was used to model normalized read coverage 
of P.  falciparum core genes as a function of log-transformed 
piperaquine IC90 in samples for which whole-genome sequence 
was available (n = 117). Read coverage of 2 genes on chromo-
some 14, plasmepsin II and III, showed the strongest association 
with piperaquine IC90 (Figure 4). Read coverage of the pfmdr1 
gene was not significantly associated with piperaquine IC90 after 
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Figure 2. Manhattan plot of the association between genome-wide parasite genotypes and piperaquine 90% inhibitory concentrations (IC90). Linear mixed models were 
used to estimate the association between single nucleotide polymorphisms (SNPs) on the DNA microarray and a continuous measure of log-transformed piperaquine IC90 (n 
= 153). The SNPs achieving genome-wide significance are shown in red. The SNPs on chromosomes 6, 10, 11, 12, and 14 were significantly associated with the phenotype. 
The SNP in PfCRT encoding the F145I mutation was not included in the microarray and was only detected by whole-genome sequencing.

















Figure  1. Distribution of piperaquine 90% inhibitory concentrations (IC90) by 
genetic subpopulation. Parasites in the genome-wide analysis grouped into 6 
genetic subpopulations. Most parasites with elevated piperaquine IC90s grouped 
together in genetic subpopulation 2 (n  =  22). Abbreviations: IC90, 90% inhibitory 
concentration; PPQ, piperaquine.
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Figure 3. Random forest variable importance plot identifying loci from the DNA microarray that best predict piperaquine 90% inhibitory concentrations (IC90). Random 
forests were used to identify loci that were the best predictors of a continuous measure of log-transformed piperaquine IC90 in samples from genetic subpopulation 2 (n = 22). 
The single nucleotide polymorphisms (SNPs) showing the greatest percentage increase in mean squared error (x-axis) are the best predictors of the phenotype. The SNPs on 
chromosomes 7, 8, 9, 10, 11, and 14 were the top predictors of log-transformed IC90.
Table 1. Single Nucleotide Polymorphisms Associated With Piperaquine 90% Inhibitory Concentrations in Fine-Mapping Analysis of Whole-Genome 
Sequence Data
SNP Gene (mutation) P value
MAL7:404010 PF3D7_0709000 (Chloroquine resistance transporter, F145I) 3.61E-07
MAL9:1233153 PF3D7_0930800 (Conserved membrane protein, T2490I) 3.61E-07
MAL9:1233160 PF3D7_0930800 (Conserved membrane protein, 2492S) 3.61E-07
MAL9:1279569 PF3D7_0932100 (Conserved membrane protein, intronic) 3.61E-07
MAL9:1279572 PF3D7_0932100 (Conserved membrane protein, intronic) 3.61E-07
MAL10:1318156 PF3D7_1032900 (RNA polymerase II–associated protein 1, 932L) 8.75E-07
MAL10:1343706 PF3D7_1033500 (WD repeat-containing protein 70, I687M) 3.61E-07
MAL10:1351775 PF3D7_1033800 (Plasmepsin VII, intronic) 3.61E-07
MAL10:1362218 PF3D7_1034100 (Conserved protein, 118G) 3.61E-07
MAL10:1369153 PF3D7_1034400 (Flavoprotein subunit of succinate dehydrogenase, Q13K) 3.61E-07
MAL10:1372810 PF3D7_1034500 (Conserved protein, C651Y) 3.61E-07
MAL10:1391842 PF3D7_1035100 (Probable protein, D133A) 3.61E-07
MAL10:1392054 PF3D7_1035100 (Probable protein, S204R) 3.61E-07
MAL10:1400026 PF3D7_1035300 (Glutamate-rich protein, P278S) 3.61E-07
MAL10:1401296 PF3D7_1035300 (Glutamate-rich protein, S701F) 3.61E-07
MAL10:1506404 PF3D7_1038000 (Antigen UB05, 51I) 3.61E-07
MAL10:1546332 PF3D7_1038400 (Gametocyte-specific protein,) 3.61E-07
MAL10:1552425 PF3D7_1038600 (Exported protein, H210R) 3.61E-07
MAL14:408912 PF3D7_1410300 (WD repeat-containing protein, 2717P) 3.61E-07
Linear mixed models were used to estimate the association between single nucleotide polymorphisms (SNPs) identified in regions of the genome in linkage disequilibrium with loci from 
Supplementary Table S5 and a continuous measure of log-transformed piperaquine 90% inhibitory concentrations (IC90) in samples that underwent whole-genome sequencing. The SNP 
corresponding to PfCRT F145I is shown in bold text and was the only locus with gene ontology terms suggesting a function in hemoglobin metabolism, drug response, or transport.
Abbreviation: SNP, single nucleotide polymorphism.
Validation Dataset
To validate the observed associations, we examined sequences 
generated from parasites collected during a study evaluating 
the therapeutic efficacy of dihydroartemisinin-piperaquine 
(n = 53) [5]. In this independent dataset, the unadjusted haz-
ard of P. falciparum recurrence in patients with parasites con-
taining >1 copy of the plasmepsin II gene (n = 34) compared 
with patients with a single copy of this gene was 5.59 (95% 
CI  =  1.30–24.06) (Table  2). The unadjusted hazard of recur-
rence in patients with parasites having the PfCRT 145I muta-
tion (n = 13) compared with those with the wildtype F145 was 
5.12 (95% CI  =  2.10–12.49). The association between PfCRT 
145I remained significant after adjusting for parasites having >1 
copy of plasmepsin II and log-transformed parasitemia at diag-
nosis (adjusted HR = 4.61; 95% CI = 1.73–12.28) (Table 2). In 
this dataset, all but 4 parasites had a PfKelch13 propeller muta-
tion, such that the presence of a PfKelch13 mutation was not 
significantly associated with recurrence and not included in the 
final model.
In addition, the mean piperaquine IC90 was significantly 
greater in parasites with both the PfCRT 145I mutation and 
multiple copies of plasmepsin II, compared with parasites with 
amplified plasmepsin II and without 145I (linear regression, 
P  =  .03) and compared with parasites with a single copy of 
plasmepsin II and without 145I (linear regression, P  =  .0001) 
(Figure 5; Supplementary Table 6). The PfCRT 145I mutation 
only occurred in parasites with amplified plasmepsin II/III.
PfCRT and Other Mutations
Within both the fine-mapping and validation datasets, 46 infec-
tions contained parasites with multiple copies of the plasmepsin 
II/III genes, 64% of which did not have the 145I mutation, and 
36% of which did have the 145I mutation. In addition, the 
PfCRT 145I mutation only occurred on a Dd2 PfCRT back-
ground (ie, in parasites with mutations at positions 75, 326, 356, 
and 371), and all parasites with 145I showed a single haplotype 
in SNPs flanking and in LD with the pfcrt gene (Supplementary 
Figure 4). All parasites with PfCRT 145I had the 580Y muta-
tion at the kelch13 locus, whereas 85% (n = 23/27) of parasites 
with amplified plasmepsin II/III but without 145I had 580Y. The 
PfCRT 97Y and 97L mutations [8] were observed in 4 and 2 
parasites, respectively, in the fine-mapping dataset. Position 
97 was not associated with piperaquine IC90 in linear mixed 
models (P = .60). The 97Y mutation was not observed, and the 
97L mutation was observed only once in parasites within the 
Table 2. Cox Proportional Hazards Models of Time to Plasmodium falci-
parum Recurrence
Variable Hazard ratio (95% CI) P value
Plasmepsin II >1 5.59 (1.30–24.06) .02
PfCRT 145I 5.12 (2.10–12.49) .0003
Plasmepsin II >1 4.14 (.89–19.37) .07
PfCRT 145I 4.61 (1.73–12.28) .002
Parasitemia at diagnosis 1.53 (1.00–2.36) .051
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Figure 4. Association between gene copy number and piperaquine 90% inhibitory concentrations (IC90). Linear regression was used to model normalized coverage of 
Plasmodium falciparum core genes in 117 whole-genome sequences as a function of log-transformed piperaquine IC90 (treated as a continuous variable). Normalized coverage 
of the plasmepsin II/III genes showed the strongest association with piperaquine IC90 (P values indicated in red).
validation dataset. No parasites in either dataset had mutations 
at PfCRT positions 343 and 353, positions implicated in a previ-
ous study of piperaquine susceptibility conducted in a different 
region of Cambodia [8].
DISCUSSION
Amplification of plasmepsin II/III is associated with decreased 
piperaquine sensitivity and may serve as a useful marker for 
surveillance [12, 13]. We performed a genome-wide associa-
tion study of ex vivo P. falciparum susceptibility to piperaquine 
to identify loci that are associated with decreased sensitivity. 
Single nucleotide polymorphisms on multiple chromosomes 
were associated with piperaquine IC90 in a genome-wide anal-
ysis. Fine-mapping of genomic regions implicated in genome-
wide analyses identified multiple SNPs in LD with each other 
that were significantly associated with piperaquine IC90, includ-
ing a mutation within the pfcrt gene. This mutation (PfCRT 
F145I) was associated with P. falciparum recurrence following 
treatment with dihydroartemisinin-piperaquine after adjusting 
for the presence of multiple copies of the plasmepsin II gene. 
Although plasmepsin II/III copy number was associated with 
piperaquine IC90 and dihydroartemisinin-piperaquine treat-
ment outcome, our data suggest that other loci may also be 
involved in resistance.
Amato and colleagues recently reported an association 
between a mutation within an exonuclease on chromosome 13 
and piperaquine IC50 [35]. We did not see any evidence of an 
association between piperaquine IC50 or IC90 and SNPs on chro-
mosome 13 in our genome-wide analysis. We did, however, see 
some overlap in SNPs identified in the Amato study and regions 
of the genome identified in our genome-wide analysis, including 
SNPs on chromosome 12 (MAL12:1787279) and chromosome 
14 (MAL14:2385550, MAL14:2395752, and MAL14:2411942). 
Wang and colleagues [36] also showed an association between 
piperaquine IC50 and an SNP in a similar region of chromo-
some 12 (MAL12:1959796), as well as an SNP on chromosome 
8 (MAL8:280180) that is in a region of the chromosome iden-
tified in our genome-wide analysis. Although these regions of 
chromosomes 8, 12, and 14 did not show significant associa-
tions in our fine-mapping analysis of whole genome sequences, 
they were identified in multiple studies and thus warrant fur-
ther investigation.
We observed a large region of LD on chromosome 10 that 
was associated with piperaquine IC90, both in the regression and 
random forest analyses. This pattern is consistent with a selec-
tive sweep localizing to this region of the genome, which har-
bors 54 genes (chromosome 10: 1318156–1552425). Of these 54 
genes, 9 (PF3D7_1033000, PF3D7_1034000, PF3D7_1034700, 
PF3D7_1036300, PF3D7_1036400, PF3D7_1036800, 
PF3D7_1037300, PF3D7_1037500, PF3D7_1038100) had gene 
ontology terms suggesting a function in hemoglobin metab-
olism, drug response, or transport, and 1 (PF3D7_1036300, 
encoding Duffy binding-like merozoite surface protein 2) has 
been implicated in resistance to halofantrine, mefloquine, and 
lumefantrine [37]. However, none of these 9 genes had poly-
morphisms that were significantly associated with piperaquine 
IC90 in our fine-mapping analysis of whole-genome sequences. 
This region of the genome is also in LD with PfCRT F145I, so 
it is not clear which mutations are driving the signal, but it is 
possible that additional loci within this region of chromosome 
10 are contributing to decreased sensitivity.
PfCRT has been implicated in previous studies of piperaquine 
susceptibility, supporting our evidence that variants of this 
transporter can contribute to resistance to this chloroquine-like 
bisquinoline. Specifically, PfCRT 101F was identified in Dd2 
parasites exposed to continuous piperaquine pressure that had 
elevated piperaquine IC50s [38], and this mutation was able to 
mediate piperaquine resistance in vitro when introduced via 
gene editing into Dd2 parasites [23]. Mutations at PfCRT posi-
tions 97, 343, and 353 have also been associated with decreased 
piperaquine sensitivity [8]. In our datasets, mutations at PfCRT 
position 97 were not associated with piperaquine IC90, and no 
mutations were observed at positions 343 and 353 in either the 
fine-mapping or validation datasets.
In this study, we only observed the PfCRT 145I mutation in 
samples collected from Oddar Meanchey province in the years 
2013–2014. Because samples were not available from other 
provinces for these years of the study (Supplementary Table  7), 
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Figure 5. Distribution of piperaquine 90% inhibitory concentrations (IC90) among 
parasites with different combinations of amplified plasmepsin II copy number and 
PfCRT 145I. Box plots indicate the distribution of piperaquine IC90 in parasites from 
the validation data set (n  =  53) in the following groups: parasites with a single 
copy of plasmepsin II and without the PfCRT 145I mutation (left), parasites with 
>1 copy of plasmepsin II and without PfCRT 145I (center), and parasites with >1
copy of plasmepsin II and with PfCRT 145I (right). The PfCRT 145I mutation only
occurred in parasites with amplified plasmepsin II copy number. Abbreviation: IC90, 
90% inhibitory concentration.
mutation in other regions of Cambodia, which is a limitation of 
the study. This mutation was not noted in other studies of piper-
aquine susceptibility that used clinical samples from Cambodia 
[12, 13]. Although these studies did not sample isolates from Oddar 
Meanchey province, they did include isolates from neighboring 
Preah Vihear province. Future studies will examine the distribu-
tion of PfCRT 145I in other geographic regions and its association 
with dihydroartemisinin-piperaquine treatment efficacy.
The PfCRT 145I mutation was only observed in parasites 
with amplified plasmepsin II/III copy number, suggesting that 
perhaps in nature this mutation has only occurred or only 
attains high frequency on a background of amplified plasmepsin 
II/III. This observation could suggest that 145I has emerged on 
a background of resistance and that its association with resis-
tance is not causal. However, this scenario is not supported by 
the observation that the association between PfCRT 145I and 
treatment outcome remained significant after adjusting for the 
presence of amplified plasmepsin II/III. Moreover, the mean 
piperaquine IC90 was greater in parasites with both amplified 
plasmepsin II/III and PfCRT 145I compared with parasites with 
just amplified plasmepsin II/III, suggesting that 145I results in 
an additional resistance effect beyond that caused by ampli-
fied plasmepsin II/III. Experiments to introduce PfCRT 145I 
into parasites both with and without elevated plasmepsin II/III 
copy number and to remove this mutation from parasites with 
elevated copy number will be important for understanding the 
independent effect of the PfCRT 145I mutation and examin-
ing any interaction between this locus and the plasmepsin II/
III genes.
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